A highly potent maytansinoid analogue and its use as a cytotoxic therapeutic agent in gold nanoparticles for the treatment of hepatocellular carcinoma. Issue 24 (15th December 2020)

• Record Type: Journal Article
• Authors: Porter, John; Ding, Yao; Hale, Sarah J.M.; Perrins, Richard D.; Robinson, Angela; Mazanetz, Michael P.; Wu, Yubo; Ma, Yinping; Conlon, Kelly; Coulter, Tom
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 30:Issue 24(2020)
• Publication Date: 2020-12-15
• Subjects: FZBVLCMFRPCICH-FLUINUAPSA-N -- YPLVZTMWISSXMW-VWAIAKSXSA-N -- DHNDNMFKFWLJKZ-BBROPENASA-N; Maytansine -- DM1 -- Gold nanoparticles -- Heptocellular carcinoma -- Nanomedicine -- Therapeutic cytotoxin -- Cancer therapy; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2020.127634
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: Gold nanoparticles are promising drug delivery agents with the potential to deliver chemotherapeutic agents to tumour sites. The highly cytotoxic maytansinoid tubulin inhibitor DM1 has been attached to gold nanoparticles and shows tumour growth inhibition in mouse models of hepatocellular carcinoma. Attempting to improve the stability of the gold-cytotoxin bond led to the design and synthesis of novel maytansinoids with improved potency in cell viability assays and improved in vivo tolerability compared to the DM1 analogues. These novel maytansines may also have applications in other methods of drug delivery, for example as the cytotoxic component of antibody drug conjugates.